Malnutrition is prevalent in hospitalised medical and surgical patients. Certain clinical factors should heighten awareness and prompt detection for malnutrition. Coding for malnutrition impacts favourably on casemix funding for a subset of malnourished patients.

No abstract

QALY, probabilistic sensitivity analysis revealed that Vedolizumab had a 97% probability of being cost-effective. CONCLUSIONS: Our model predicted that treatment with Vedolizumab improves QALYs and increases time in remission and response compared with Infliximab. In the context of Thailand, Vedolizumab was cost saving and dominated intervention for biologicnaïve patients with moderately to severely active UC.